Type:Injection
Generic Name:Pegfilgrastim
Manufacturer:Healthcare Pharmaceuticals Ltd.
Price:৳20300.00
Chemotherapy induced-neutropenia, Bone marrow stimulation
Subcutaneous Chemotherapy-induced neutropenia, Myelosuppressive Chemotherapy Adjunct Indicated to decrease incidence of infection in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy assoc with febrile neutropenia Adult: 6 mg as a single dose for each chemotherapy cycle, given at least 24 hr after cytotoxic chemotherapy.
Subcutaneous Prevention of Chemotherapy Induced Neutropenia <45 kg: 100 mcg/kg per chemotherapy cycle; not to exceed 6 mg/dose; do not administer in the period 14 days before and 24-72 hr after administration of cytotoxic chemotherapy >45kg: 6 mg SC once per chemotherapy cycle; do not administer in the period 14 days before and 24 hr after administration of cytotoxic chemotherapy
Hypersensitivity to Pegfilgrastim or filgrastim; or to any ingredients in the formulation.
Pegfilgrastim is a covalent conjugate of filgrastim and monomethoxypolyethyleneglycol (PEG). It is a colony-stimulating factor which binds to specific cell surface receptors of haematopoietic cells, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation. Pegfilgrastim has delayed renal clearance and prolonged half-life relative to filgrastim as a result of conjugation with PEG.
Splenic rupture (including fatal cases) or enlarged spleen have been reported following admin of Pegfilgrastim; patients who reported left upper abdominal or shoulder tip pain should be evaluated for development of splenomegaly or splenic rupture. Acute respiratory distress syndrome (ARDS) may occur; monitor patients for pulmonary symptoms e.g. cough, fever, lung infiltrates, or respiratory distress. Discontinue or withhold Pegfilgrastim in patients with confirmed ARDS. Caution in patients with existing sickle cell disorders; as severe sickle cell crisis may occur. Possibility of Pegfilgrastim acting as a growth factor for any tumor type cannot be excluded. Not approved for myeloid malignancies and myelodysplasia. Monitor platelet count and haematocrit regularly. Do not administer Pegfilgrastim during the 14 days before and 24 hr after chemotherapy admin due to the potential sensitivity of rapidly dividing myeloid cells to cytotoxic chemotherapy. Safety and efficacy in paediatric patients have not been established. Pregnancy and lactation.
>10% Peripheral edema (12%),Asthenia (13%),Headache (16%),Vomiting (13%),Bone pain (31-57%),Myalgia (21%),Weakness (13%),Alopecia (15-72%),Pyrexia (23%) Frequency Not Defined Acute respiratory distress syndrome,Sickle cell crisis,Splenic rupture,Hyperuricemia,Elevated lactate dehydrogenase,Elevated alkaline phosphatase,Allergic reaction Potentially Fatal: Anaphylaxis.
Colony-stimulating factors such as Pegfilgrastim should not be given at the same time as cytotoxic chemotherapy due to the increased risk of myelosuppression.
